Patents Examined by Padma Baskar
  • Peptides for chlamydophila pneumoniae vaccine and diagnosis
    Patent number: 7223836
    Abstract: Peptides are disclosed that include SEQ ID NO:1, SEQ ID NO: 2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, and SEQ ID NO:6, or a conservative variant or mimic thereof, wherein the conservative variant or mimic specifically binds an antibody that specifically binds SEQ ID NO:1, SEQ ID NO: 2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID or NO:6. These peptides are of use in generating an immune response against C. pneumoniae, or in preventing infection with against C. pneumoniae.
    Type: Grant
    Filed: May 31, 2002
    Date of Patent: May 29, 2007
    Assignee: The United States of America as represented by the Secretary of the Department of Health and Human Services, Centers for Disease Control and Prevention
    Inventors: Eric L. Marston, Jackie S. Sampson, George M. Carlone, Edwin W. Ades
  • Vaccine composition
    Patent number: 7220415
    Abstract: A polypeptide is described herein which comprises (a) the sequence of SEQ ID No. 2, (b) a variant of (a) which is capable of generating a protective immune response to S. pyogenes, or (c) a fragment of (a) or (b) of at least 6 amino acids in length which is capable of generating a protective immune response to S. pyogenes, in the manufacture of medicament for use as a vaccine against S. pyogenes. A pharmaceutical composition for use in vaccinating against S. pyogenes or Group B streptococcus comprises a polypeptide which comprises: (A) the amino acid sequence of SEQ ID No. 2, (B) a variant of (A) which is capable of conferring protective immunity to S. pyogenes or Group B streptococcus, or (C) a fragment of (A) or (B) of at least 6 amino acids in length which is capable of conferring protective immunity to S. pyogenes or Group B streptococcus.
    Type: Grant
    Filed: May 5, 2000
    Date of Patent: May 22, 2007
    Assignee: Gunnar Lindahl
    Inventors: Margaretha Stalhammar-Carlemalm, Thomas Areschoug, Charlotte Larsson, Gunnar Lindahl
  • : a gene, methods for making and using, and targeting it or its expression products for antifungal applications
    Patent number: 7217538
    Abstract: Disclosed and claimed is the CaESS1 gene, portions thereof such as primers or probes, expression products therefrom, and methods for using the gene, and expression products; for instance, for diagnostic, therapeutic or preventive compositions.
    Type: Grant
    Filed: January 15, 2003
    Date of Patent: May 15, 2007
    Assignee: Health Research Incorporated
    Inventors: Steven D Hanes, Gina Devasahayam, Vishnu Chaturvedi
  • Aconitase
    Patent number: 7183100
    Abstract: A bacterial protein which converts 2-methyl citrate to 2-methyl isocitrate is a previously unknown target for antibacterial agents. The protein of this activity is associated with mucoid bacteria and inhibitors of production or activity of this protein in combination with propionic acid mitigate the virulence of these bacteria.
    Type: Grant
    Filed: May 19, 2003
    Date of Patent: February 27, 2007
    Assignee: Biological Targets, Inc.
    Inventors: Mehmet Candas, Lee A. Bulla
  • Nucleic acid and amino acid sequences relating to for diagnostics and therapeutics
    Patent number: 7183083
    Abstract: The invention provides isolated polypeptide and nucleic acid sequences derived from Staphylococcus epidermidis that are useful in diagnosis and therapy of pathological conditions; antibodies against the polypeptides; and methods for the production of the polypeptides. The invention also provides methods for the detection, prevention and treatment of pathological conditions resulting from bacterial infection.
    Type: Grant
    Filed: December 1, 2003
    Date of Patent: February 27, 2007
    Assignee: Wyeth
    Inventors: Lynn Doucette-Stamm, David Bush
  • Multifunctional monoclonal antibodies directed to peptidoglycan of gram-positive bacteria
    Patent number: 7169903
    Abstract: The present invention encompasses protective monoclonal antibodies that bind to peptidoglycan of Gram-positive bacteria. The antibodies also bind to whole bacteria and enhance phagocytosis and killing of the bacteria in vitro and block nasal colonization by Gram-positive bacteria in vivo. The invention also provides human, humanized and chimeric antibodies. The invention also sets forth the heavy chain and light chain variable regions of an antibody within the invention.
    Type: Grant
    Filed: December 20, 2002
    Date of Patent: January 30, 2007
    Assignee: Biosynexus Incorporated
    Inventors: Richard F. Schuman, John Fitzgerald Kokai-Kun, Simon J. Foster, Jeffrey R. Stinson, Gerald Walter Fischer
  • Antigenic peptide fragments of VapA protein, and uses thereof
    Patent number: 7169393
    Abstract: An isolated peptide fragment of the VapA protein that binds antibodies specific for Rhodococcus equi and the VapA protein. In a preferred form the peptide contains an amino acid sequence of 5 or more amino acid residues that is identical to or homologous to the amino acid sequence of at least one region of the VapA protein that is responsible for immunological recognition. Methods of diagnosing a vertebrate for the presence of R. equi using the peptide and methods of vaccinating a vertebrate against R. equi using the peptide are also claimed.
    Type: Grant
    Filed: April 27, 2001
    Date of Patent: January 30, 2007
    Assignee: Rural Industries Research & Development Coporation
    Inventors: Thiru Vanniasinkam, Mary Barton, Michael W Heuzenroeder
  • Nucleic acid and amino acid sequences relating to for diagnostics and therapeutics
    Patent number: 7153952
    Abstract: The invention provides isolated polypeptide and nucleic acid sequences derived from Streptococcus pneumoniae that are useful in diagnosis and therapy of pathological conditions; antibodies against the polypeptides; and methods for the production of the polypeptides. The invention also provides methods for the detection, prevention and treatment of pathological conditions resulting from bacterial infection.
    Type: Grant
    Filed: December 30, 2004
    Date of Patent: December 26, 2006
    Assignee: sanofi pasteur limited/sanofi pasteur limitée
    Inventors: Lynn Doucette-Stamm, David Bush, Qiandong Zeng, Timothy Opperman, Chad Eric Houseweart
  • Recombinant merozoite protein-1 p42 vaccine
    Patent number: 7150875
    Abstract: In this application is the expression and purification of a recombinant Plasmodium vivax (SalI) PvMSP-1 p42. The method of the present invention produces a highly purified protein which retains folding and disulfide bridging of the native molecule. The recombinant PvMSP-1 p42 is useful as a diagnostic reagent, for use in antibody production, and as a vaccine.
    Type: Grant
    Filed: March 18, 2002
    Date of Patent: December 19, 2006
    Assignee: The United States of America as represented by the Secretary of the Army
    Inventors: David E. Lanar, Sheetij Dutta, Lisa A. Ware
  • Nucleic acid and amino acid sequences relating to for diagnostics and therapeutics
    Patent number: 7151171
    Abstract: The invention provides isolated polypeptide and nucleic acid sequences derived from Streptococcus pneumoniae that are useful in diagnosis and therapy of pathological conditions; antibodies against the polypeptides; and methods for the production of the polypeptides. The invention also provides methods for the detection, prevention and treatment of pathological conditions resulting from bacterial infection.
    Type: Grant
    Filed: December 30, 2004
    Date of Patent: December 19, 2006
    Assignee: Sanofi Pasteur Limited/Sanofi Pasteur Limitée
    Inventors: Lynn Doucette-Stamm, David Bush, Qiandong Zeng, Timothy Opperman, Chad Eric Houseweart
  • Coccidiosis vaccines
    Patent number: 7150873
    Abstract: The present invention relates to hydrophilic Eimeria polypeptides, DNA-fragments encoding those peptides, recombinant DNA molecules comprising such DNA-fragments, live recombinant carriers comprising such DNA-fragments or recombinant DNA molecules and host cells comprising such DNA-fragments, recombinant DNA molecules or live recombinant carriers. Furthermore, the invention relates to antibodies against the polypeptides and to coccidiosis vaccines based upon said polypeptides. The invention also relates to methods for the preparation of such antibodies and vaccines, and to methods for the detection of Eimeria parasites and antibodies against Eimeria parasites.
    Type: Grant
    Filed: November 26, 2003
    Date of Patent: December 19, 2006
    Assignee: Intervet International B.V.
    Inventors: Theodorus Cornelis Schaap, Catharina Maria Kuiper, Arnoldus Nicolaas Vermeulen
  • Nuclear protein
    Patent number: 7151162
    Abstract: An isolated Shoca polypeptide comprising: (i) the amino acid sequence of SEQ ID NO: 2 or SEQ ID NO: 4; or (ii) a variant thereof which is capable of interacting with a polypeptide of the wnt signalling pathway; or (iii) a fragment of (i) or (ii) which is capable of interacting with a polypeptide of the wnt signalling pathway, a polypeptide encoding said polypeptide, a method for identifying a modulator of the wnt signalling pathway utilising said polypeptide or polynucleotide and methods of diagnosing and treating cancer.
    Type: Grant
    Filed: December 4, 2002
    Date of Patent: December 19, 2006
    Assignee: The University of Children's Hospital of Both Cantons of Basel
    Inventor: Georg Andreas Hollander
  • GIPs, a family of polypeptides with transcription factor activity that interact with goodpasture antigen binding protein
    Patent number: 7147855
    Abstract: The present invention provides isolated GPBP-interacting 90 and 130 kDa polypeptides, and portions thereof (GIP90/130 polypeptides), antibodies to the GIP90/130 polypeptides, and pharmaceutical compositions thereof. The present invention also provides isolated GIP90/130 nucleic acid sequences, expression vectors comprising the nucleic acid sequences, and host cells transfected with the expression vectors. The invention further provides methods for detecting the GIP90/130 polypeptides or nucleic acid sequences, methods for inhibiting interactions between GPBP and GIP90/130 polypeptides, between pol k76 and GIP90/130 polypeptides or aggregation of GIP90/130 polypeptides, and methods for treating patients with autoimmune disorders or cancer.
    Type: Grant
    Filed: December 4, 2002
    Date of Patent: December 12, 2006
    Inventors: Juan Saus, Francisco Revert-Ros
  • Nucleic acid and amino acid sequences relating to for diagnostics and therapeutics
    Patent number: 7135560
    Abstract: The invention provides isolated polypeptide and nucleic acid sequences derived from Streptococcus pneumoniae that are useful in diagnosis and therapy of pathological conditions; antibodies against the polypeptides; and methods for the production of the polypeptides. The invention also provides methods for the detection, prevention and treatment of pathological conditions resulting from bacterial infection.
    Type: Grant
    Filed: December 30, 2004
    Date of Patent: November 14, 2006
    Assignee: sanofi pasteur limited
    Inventors: Lynn Doucette-Stamm, David Bush, Qiandong Zeng, Timothy Opperman, Chad Eric Houseweart
  • Medicament for the treatment of chlamydial infection
    Patent number: 7132512
    Abstract: The present invention concerns treatment, prevention and diagnosis of infection due to Chlamydia pneumoniae and, in particular, to the prevention and treatment of atherosclerosis, including coronary atherosclerosis, caused by same.
    Type: Grant
    Filed: August 6, 2003
    Date of Patent: November 7, 2006
    Assignee: NeuTec Pharma PLC
    Inventors: James Peter Burnie, Ruth Christine Matthews
  • Nucleic acid and amino acid sequences relating to for diagnostics and therapeutics
    Patent number: 7129340
    Abstract: The invention provides isolated polypeptide and nucleic acid sequences derived from Streptococcus pneumoniae that are useful in diagnosis and therapy of pathological conditions; antibodies against the polypeptides; and methods for the production of the polypeptides. The invention also provides methods for the detection, prevention and treatment of pathological conditions resulting from bacterial infection.
    Type: Grant
    Filed: December 30, 2004
    Date of Patent: October 31, 2006
    Assignee: sanofi pasteur limited/sanofi pasteur limitée
    Inventors: Lynn Doucette-Stamm, David Bush, Qiandong Zeng, Timothy Opperman, Chad Eric Houseweart
  • Nucleic acid and amino acid sequences relating to for diagnostics and therapeutics
    Patent number: 7129339
    Abstract: The invention provides isolated polypeptide and nucleic acid sequences derived from Streptococcus pneumoniae that are useful in diagnosis and therapy of pathological conditions; antibodies against the polypeptides; and methods for the production of the polypeptides. The invention also provides methods for the detection, prevention and treatment of pathological conditions resulting from bacterial infection.
    Type: Grant
    Filed: December 30, 2004
    Date of Patent: October 31, 2006
    Assignee: sanofi pasteur limited
    Inventors: Lynn Doucette-Stamm, David Bush, Qiandong Zeng, Timothy Opperman, Chad Eric Houseweart
  • Compounds from
    Patent number: 7122197
    Abstract: The invention provides BASB020 polypeptides and polynucleotides encoding BASB020 polypeptides and methods for producing such polypeptides by recombinant techniques. Also provided are diagnostic, prophylactic and therapeutic uses.
    Type: Grant
    Filed: May 7, 1999
    Date of Patent: October 17, 2006
    Assignee: SmithKline Beecham Biologicals S.A.
    Inventor: Joelle Thonnard
  • Nucleic acid and amino acid sequences relating to for diagnostics and therapeutics
    Patent number: 7115731
    Abstract: The invention provides isolated polypeptide and nucleic acid sequences derived from Streptococcus pneumoniae that are useful in diagnosis and therapy of pathological conditions; antibodies against the polypeptides; and methods for the production of the polypeptides. The invention also provides methods for the detection, prevention and treatment of pathological conditions resulting from bacterial infection.
    Type: Grant
    Filed: December 30, 2004
    Date of Patent: October 3, 2006
    Assignee: sanofi pasteur limited/ sanofi pasteur limiteé
    Inventors: Lynn Doucette-Stamm, David Bush, Oiandong Zeng, Timothy Opperman, Chad Eric Houseweart
  • Methods and compositions for detecting larval with a cloned diagnostic antigen
    Patent number: 7094576
    Abstract: Compositions and methods for the detection of Taenia solium and the diagnosis of T. solium infection are described. The nucleotide and amino acid sequences of the antigenic T. solium polypeptides gp50a, gp50b and gp50c are provided. The compositions contain synthetic antigenic polypeptides of larval origin prepared using the sequences described herein. Probes and primers for the detection or amplification of T. solium nucleic acid molecules are also described. The polypeptides can be administered to a human or animal to protect against T. solium infection. In addition, the polypeptides are useful as research tools for studying T. solium and as reagents in assays for the detection of T. solium antibodies in a biological sample. The methods are sensitive and specific assays that utilize the stable recombinant or synthetic antigenic polypeptides or nucleic acid molecules encoding the larval polypeptides.
    Type: Grant
    Filed: March 30, 2001
    Date of Patent: August 22, 2006
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: Victor C. W. Tsang, Ryan M. Greene, Patricia P. Wilkins, Kathy Hancock